Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Swine Flu (A/H1n1) Information for Pharmaceutical Society of Australia Members
- Novavax Announces Selection Of A Respiratory Syncytial Virus Vaccine Candidate For Advanced Preclinical Studies
- St. Jude And UF Proton Therapy Institute To Begin Proton Therapy Clinical Trial
- New Breast MRI Technology Enables Enhanced Breast Cancer Detection
- Study Confirms That Cannabis Is Beneficial For Multiple Sclerosis
- DaVita Study Demonstrates Clinical Application Of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
- FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
- Report Finds Racial Disparities In Prescription Drug Access, Use, Regimen Adherence
- Artificial Liver For Drug Tests
- Lethality Of H1N1 Influenza Virus Increasing According To Latest Analysis Of Virus Peptide Genomic Data
Genetically-Engineered MSCs Kill Metastatic Lung Cancer Cells In Mice
Posted by: admin in Pharmacy Drugs on October 27th, 2009
Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors.
The genetically engineered stem cells are able to home to the cancer cells, both in culture and in mouse models, and deliver TNF-related apoptosis-inducing ligand (TRAIL), destroying the tumor cells while sparing normal cells.
The research will be presented on Tuesday, May 19, at the American Thoracic Society’s 105th International Conference in San Diego.
“Present oncological therapies are limited by host toxicity,” said Michael Loebinger, M.D., M.A, who, along with S. M. Janes, M.D., Ph.D., conducted the research at the Centre for Respiratory Research at the University College of London. “They are also limited by cancer resistance and may not destroy cancer stem cells.”
With these experiments, the investigators combined two disparate areas of research that they believed held promise for treating cancer. Studies had shown that MSCs can be used as vectors to deliver anti-tumor therapy, while other studies found that TRAIL killed cancer cells, but not normal cells.
For their experiments, Drs. Loebinger and Janes identified those cells likely to be resistant to therapies (cancer cells that have characteristics of stem cells) and found that they were just as likely to be destroyed as tumor cells by this novel therapy.
In culture, the stem cells caused lung, squamous, breast and cervical cancer cells to die (all p<0.01), even at low stem cell/tumor cell ratios (1:16).
In mice, the researchers showed that the stem cells could reduce the growth of subcutaneous breast tumors by approximately 80 percent (p<.0001). The stem cells could also be injected intravenously as therapy for mice with lung metastases and could eliminate lung metastases in 38 percent of mice compared to control mice, all of which still had metastases (p=0.03).
It is the first study to intravenously introduce MSCs that have been genetically modified to deliver TRAIL. Drs. Loebinger and Janes chose the breast cancer cells for both models because in their in vitro experiments, the MSCs “demonstrated a particularly strong homing to breast cancer cells.”
“Breast cancer tumors are a good model of metastases,” added Dr. Loebinger, “but our plan is to test the engineered stem cells with other models, including lung cancer.”
While not fully understood, Dr. Loebinger added, the homing of the engineered cells appears to be a characteristic of MSCs themselves.
The authors conclude that, “this is the first study to demonstrate a significant reduction in tumor burden with inducible TRAIL-expressing MSCs in a well-controlled and specifically directed therapy.”
They believe that human trials of TRAIL-expressing MSCs could begin in two or three years.
Funding for this research was provided by the Medical Research Council UK.
Source: American Thoracic Society (ATS)
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.